Caricamento...
Extended interval dosing of natalizumab: a two-center, 7-year experience
BACKGROUND: The enthusiasm for natalizumab, a highly efficacious agent in the treatment of multiple sclerosis (MS), has been tempered by the risks of progressive multifocal leukoencephalopathy associated with its use, and strategies to minimize those risks are of great interest. Extended interval do...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4206618/ https://ncbi.nlm.nih.gov/pubmed/25342976 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285614540224 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|